Radioactive 'Tumor Hunter' drug enters human trials for tough cancers

NCT ID NCT04939610

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing a new radioactive drug called 177Lu-FAP-2286 for people with advanced solid tumors that have stopped responding to other treatments. The drug is designed to find and deliver radiation directly to tumors by targeting a specific protein common in many cancers. The first part of the study will find a safe dose, and the second part will see how well it works alone or with chemotherapy for specific cancers like pancreatic, lung, and breast cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Columbia University Medical Center
RECRUITING

New York, New York, 10032, United States

Contact Email: •••••@•••••

Contact
Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109-1023, United States
Hoag Hospital Irvine
RECRUITING

Irvine, California, 92618, United States

Contact Email: •••••@•••••

Contact
Karmanos Cancer Institute
RECRUITING

Detroit, Michigan, 48201, United States
Mayo Clinic
RECRUITING

Jacksonville, Florida, 32224, United States
Mayo Clinic
RECRUITING

Rochester, Minnesota, 55905, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Novartis Investigative Site
RECRUITING

Adelaide, South Australia, 5000, Australia
Novartis Investigative Site
RECRUITING

Melbourne, Victoria, 3000, Australia

Contact

Contact Email: •••••@•••••
Novartis Investigative Site
RECRUITING

Melbourne, Victoria, 3004, Australia
Novartis Investigative Site
RECRUITING

Montreal, Quebec, H4A 3J1, Canada
Novartis Investigative Site
RECRUITING

Meldola, Emilia-Romagna, 47014, Italy
Novartis Investigator Site
RECRUITING

Montpellier, Cedex 5, 34298, France
Novartis Investigator Site
RECRUITING

Bordeaux, 33000, France
Novartis Investigator Site
RECRUITING

Clermont-Ferrand, 63011, France
Novartis Investigator Site
RECRUITING

Vandœuvre-lès-Nancy, 54511, France
Oregon Health and Science University
RECRUITING

Portland, Oregon, 97239-3098, United States
Saint Louis University Hospital
RECRUITING

St Louis, Missouri, 63110-2539, United States
UAB Comprehensive Cancer Center
RECRUITING

Birmingham, Alabama, 35233, United States

Contact Email: •••••@•••••

Contact
UCSF Medical Center
RECRUITING

San Francisco, California, 94158, United States

Contact Email: •••••@•••••

Contact
UNC Hospitals
RECRUITING

Chapel Hill, North Carolina, 27514, United States
UPMC Hillman Cancer Center
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States
Univ of Utah, Huntsman Cancer Institute
RECRUITING

Salt Lake City, Utah, 84112, United States
University of California Los Angeles (UCLA)
RECRUITING

Los Angeles, California, 90095, United States

Contact

Contact Phone: •••-•••-••••
University of Chicago Medical Center
RECRUITING

Chicago, Illinois, 60637, United States
University of Iowa Hospitals and Clinics
RECRUITING

Iowa City, Iowa, 52242, United States

Contact Email: •••••@•••••

Contact
University of Miami Hospital and Clinics
RECRUITING

Miami, Florida, 33136, United States

Contact Email: •••••@•••••

Contact
University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.

SOLID TUMOR